FIGURE 1.
FIGURE 2.
Clinical characteristics of participants at beginning of the study and after one-year post-chemotherapy
| Characteristic | At inclusion-before chemotherapy (n = 102) n (%) | One year after end of chemotherapy (n = 71) n (%) |
|---|---|---|
| Tumour stage | ||
| T1 | 6 (45.1) | 32 (44.4) |
| T2 | 43 (42.2) | 33 (45.8) |
| T3 | 13 (12.7) | 7 (9.7) |
| Lymph node stage | ||
| N0 | 43 (42.2) | 31 (43.1) |
| N1 | 38 (37.3) | 30 (41.7) |
| N2 | 12 (11.8) | 9 (12.5) |
| N3 | 9 (8.8) | 2 (2.8) |
| Tumour subtype | ||
| Luminal A-like | 12 (11.8) | 7 (9.7) |
| Luminal B-like | 47 (46.1) | 35 (48.6) |
| Luminal B HER2 positive | 19 (18.6) | 14 (19.4) |
| HER2 positive | 8 (7.8) | 6 (8.3) |
| Triple-negative | 16 (15.7) | 10 (13.9) |
| Type of surgery | ||
| Breast-conserving surgery + Sentinel node biopsy | 37 (36.3) | 28 (38.9) |
| Breast-conserving surgery + Axillary dissection | 14 (13.7) | 11 (15.3) |
| Mastectomy + Sentinel node biopsy | 23 (22.5) | 15 (20.8) |
| Mastectomy + Axillary dissection | 28 (27.5) | 18 (25.0) |
| Breast reconstruction | ||
| None | 78 (76.5) | 55 (76.4) |
| Deep inferior flap | 13 (12.7) | 10 (13.9) |
| Tissue expander, followed by silicone implant | 11 (10.8) | 7 (9.7) |
| Chemotherapy type | ||
| Anthracyclines and taxanes | 70 (68.7) | 51 (70.8) |
| Anthracyclines only | 19 (18.6) | 13 (18.1) |
| Taxanes only | 10 (9.8) | 6 (8.3) |
| CMF | 3 (2.9) | 2 (2.8) |
| Anti-HER2 therapy | 27 (26.4) | 20 (27.8) |
| Adjuvant endocrine therapy | 78 (76.5) | 57 (79.2) |
| Radiotherapy | 81 (79.4) | 59 (81.9) |
Patient-reported outcomes presented by EORTC C30 Summary Score (C-30 SumSc) and global health status/quality of life (GHS) at inclusion (beginning of chemotherapy), one-year post-chemotherapy, and the difference among both times
| Predicted | At inclusion | At 1 year | [1 year] - [At inclusion] | |||||
|---|---|---|---|---|---|---|---|---|
| n | mean | Mean (95% CI) | p | Mean (95% CI) | p | Mean (95% CI) | p | |
| C-30 SumSc | 70 | 90.9 | 88.5 (86.1, 90.8) | 0.04 | 82 (78.4, 85.5) | < 0.001 | −6.5 (−9.6, −3.4) | < 0.001 |
| GHS | 71 | 72.7 | 71.1 (66.7, 75.6) | 0.50 | 69.6 (65, 74.2) | 0.19 | −1.5 (−6.6, 3.5) | 0.55 |